GlassScriptPhysician profile
Thomas A Lupoli
NPI 1174717276
$6,754.74
in general payments reported to CMS, 2019-2025
27 companies · $972 in 2025
The $972 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $790 · 2021: $794 · 2022: $966 · 2023: $979 · 2024: $807 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717 · Education: $40.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.95 |
| Education | $40.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,733.98 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $809.02 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $782.63 | 2019-2025 | Dupixent |
| Csl Behring | $457.66 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $424.99 | 2019-2025 | |
| Genzyme Corporation | $341.07 | 2019-2025 | |
| Grifols USA, LLC | $296.06 | 2020-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $256.25 | 2021-2025 | Cuvitru |
| Optinose US, INC. | $241.84 | 2019-2025 | |
| Genentech USA, INC. | $228.15 | 2019-2025 | Xolair |
| Pfizer INC. | $222.90 | 2019-2025 | |
| Pharming Healthcare, INC. | $150.14 | 2021-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $107.09 | 2021-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.58 | 2019-2023 | Stiolto Respimat |
| Octapharma USA, INC. | $93.77 | 2021-2024 | Cutaquig |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87.49 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $68.91 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Kaleo, INC. | $63.94 | 2020-2021 | |
| Incyte Corporation | $53.23 | 2022-2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2019 | |
| Blueprint Medicines Corporation | $41.98 | 2023-2024 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $41.39 | 2021 | |
| Lilly USA, LLC | $24.13 | 2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $23.96 | 2021 | |
| Gc Biopharma USA, INC. | $23.76 | 2025 | Alyglo |
| Horizon Therapeutics Plc | $18.24 | 2021 | |
| Hikma Pharmaceuticals USA | $15.13 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lupoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.